IPO raises £7.5m for novel cancer treatment
BiVictriX Therapeutics plc, an emerging biotechnology company that develops new cancer therapies, began trading on London's alternative investment market (Aim) on Wednesday following its IPO.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts